The IL6 role in NASH is controversial since it was postulated that is a key factor in the progression of this disease and the development of IR [59] and other researchers have assumed that IL6 may limit endotoxemia and obesity-associated IR [60]. Here, IL6 is linked to metabolic dysfunction-associated steatohepatitis.